197 related articles for article (PubMed ID: 30813931)
1. A critical role of epigenetic inactivation of miR-9 in EVI1
Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
[TBL] [Abstract][Full Text] [Related]
2. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.
Li F; He W; Geng R; Xie X
Clin Transl Oncol; 2020 Jan; 22(1):137-143. PubMed ID: 31054042
[TBL] [Abstract][Full Text] [Related]
3. Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.
Saha HR; Kaneda-Nakashima K; Shimosaki S; Suekane A; Sarkar B; Saito Y; Ogoh H; Nakahata S; Inoue K; Watanabe T; Nagase H; Morishita K
Sci Rep; 2018 Sep; 8(1):13741. PubMed ID: 30214063
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
5. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
6. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
Kotaki R; Higuchi H; Ogiya D; Katahira Y; Kurosaki N; Yukihira N; Ogata J; Yamamoto H; Mohamad Alba S; Azhim A; Kitajima T; Inoue S; Morishita K; Ono K; Koyama-Nasu R; Kotani A
Int J Hematol; 2017 Dec; 106(6):811-819. PubMed ID: 28831750
[TBL] [Abstract][Full Text] [Related]
7. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
[TBL] [Abstract][Full Text] [Related]
8. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
10. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.
Qin YZ; Zhao T; Zhu HH; Wang J; Jia JS; Lai YY; Zhao XS; Shi HX; Liu YR; Jiang H; Huang XJ; Jiang Q
Med Sci Monit; 2018 Feb; 24():758-767. PubMed ID: 29408852
[TBL] [Abstract][Full Text] [Related]
11. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
12. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Yan-Fang T; Jian N; Jun L; Na W; Pei-Fang X; Wen-Li Z; Dong W; Li P; Jian W; Xing F; Jian P
BMC Med Genet; 2013 Jul; 14():74. PubMed ID: 23870168
[TBL] [Abstract][Full Text] [Related]
13. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation.
Mizuno H; Koya J; Masamoto Y; Kagoya Y; Kurokawa M
Cancer Sci; 2021 Oct; 112(10):4112-4126. PubMed ID: 34363719
[TBL] [Abstract][Full Text] [Related]
14. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.
Bao F; Zhang L; Pei X; Lian C; Liu Y; Tan H; Lei P
PLoS One; 2021; 16(9):e0256995. PubMed ID: 34587164
[TBL] [Abstract][Full Text] [Related]
15. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.
Senyuk V; Zhang Y; Liu Y; Ming M; Premanand K; Zhou L; Chen P; Chen J; Rowley JD; Nucifora G; Qian Z
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5594-9. PubMed ID: 23509296
[TBL] [Abstract][Full Text] [Related]
16. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
17. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
18. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract][Full Text] [Related]
20. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
